Inpatient treatment of depression and associated hospital charges

被引:14
作者
Ackerman, DL
Unützer, J
Greenland, S
Gitlin, M
机构
[1] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Inst Neuropsychiat, Ctr Hlth Serv Res, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Psychiat, Los Angeles, CA 90024 USA
关键词
depression; drug utilization; pharmacoeconomic; inpatient;
D O I
10.1002/pds.694
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective We evaluated inpatient treatment of depression, prescribing patterns for antidepressants, and associated hospital charges. Methods We reviewed administrative data of the UCLA Neuropsychiatric Hospital between July 1994 and July 1997 for all 1698 hospitalizations for mood disorders. We evaluated drug utilization patterns and hospital charges by analysis of variance and multiple regression, and by stratifying on diagnosis, severity, age, and other factors. Results Length of stay was the major contributor to total charges, which included room charges and charges for services, procedures, supplies. and tests. The selective serotonin reuptake inhibitors (SSRIs) were prescribed most often (to 47% of patients), followed by the atypicals (heterocyclics, 12%), the tricyclics (TCAs, 7%), venlafaxine (7%) and the monoamine oxidase inhibitors (MAOIs, <1%). The atypicals were given to the oldest patients, After controlling for length of stay, patient age, genders and comorbidity, the atypicals were associated with the highest total inpatient charges: $2000 more than MAOIs, $600 more than SSRIs, and $600 more than venlafaxine. Higher charges were the result of more expensive procedures, especially ECT. Discussion The SSRls were the most commonly used antidepressant. Charges for antidepressant medications contributed only 0.5% of total inpatient charges. Patients receiving atypicals had among the highest total charges, partly because of the higher use of ECT. They may represent a more severely depressed group who have not responded to other antidepressants. Copyright (C) 2002 John Wiley & Sons, Ltd.
引用
收藏
页码:219 / 227
页数:9
相关论文
共 38 条
[1]   A COMPARISON OF INPATIENT AND OUTPATIENT PRESCRIBING [J].
ANDERSON, DN .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :644-649
[2]  
ANTON SF, 1995, PSYCHOPHARMACOL BULL, V31, P249
[3]   COST-ANALYSIS OF PAROXETINE VERSUS IMIPRAMINE IN MAJOR DEPRESSION [J].
BENTKOVER, JD ;
FEIGHNER, JP .
PHARMACOECONOMICS, 1995, 8 (03) :223-232
[4]  
BRYANT SG, 1990, J CLIN PSYCHIAT, V51, P27
[5]  
BURKE MJ, 1994, J CLIN PSYCHIAT, V55, P42
[6]   Economic comparisons of the pharmacotherapy of depression: an overview [J].
Crott, R ;
Gilis, P .
ACTA PSYCHIATRICA SCANDINAVICA, 1998, 97 (04) :241-252
[7]   Sertraline - A pharmacoeconomic evaluation of its use in depression [J].
Davis, R ;
Wilde, MI .
PHARMACOECONOMICS, 1996, 10 (04) :409-431
[8]  
Dewan M J, 1992, J Geriatr Psychiatry Neurol, V5, P40
[9]   Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment [J].
Egberts, ACG ;
Lenderink, AW ;
deKoning, FHP ;
Leufkens, HGM .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (03) :149-155
[10]   A MODEL TO EVALUATE THE COST-EFFECTIVENESS OF ORAL THERAPIES IN THE MANAGEMENT OF PATIENTS WITH MAJOR DEPRESSIVE-DISORDERS [J].
EINARSON, TR ;
ARIKIAN, S ;
SWEENEY, S ;
DOYLE, J .
CLINICAL THERAPEUTICS, 1995, 17 (01) :136-153